NRXP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 21.06%

Insider Buying (Last 12 Months): $75,200.00

Insider Selling (Last 12 Months): $0.00

NRx Pharmaceuticals Insider Trading History Chart

NRx Pharmaceuticals Share Price & Price History

^$3.14

▲ +0.02 (0.64%)

As of 04/25/2024 01:00 AM ET

Days: 30 | 90 | 365

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

NRx Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/30/2023	Aaron Gorovitz	Director	Buy	3,500	$3.20	$11,200.00	10,500
8/22/2023	Jonathan C Javitt	Insider	Buy	20,000	$3.20	$64,000.00	34,633
12/16/2022	Stephen H Willard	CEO	Buy	5,000	$11.70	$58,500.00	5,000
12/16/2022	Voorhees Seth Van	CFO	Buy	3,000	$11.00	$33,000.00	4,633
12/7/2022	Jonathan C Javitt	Director	Sell	40,000	$10.00	$400,000.00	1,289,999
11/29/2022	Daniel C Javitt	Major Shareholder	Sell	1,373	$15.00	$20,595.00	964,323
11/28/2022	Patrick John Flynn	Director	Buy	175	$12.50	$2,187.50	175
11/25/2022	Voorhees Seth Van	CFO	Buy	1,633	$11.10	$18,126.30	1,637
11/18/2022	Chaim Hurvitz	Director	Buy	4,040	$11.00	$44,440.00	50,000
11/17/2022	Daniel C Javitt	Major Shareholder	Sell	3,301	$10.50	$34,660.50	965,696
11/16/2022	Chaim Hurvitz	Director	Buy	28,781	$9.90	$284,931.90	28,781
11/11/2022	Daniel C Javitt	Major Shareholder	Sell	4,920	$10.10	$49,692.00	982,370
7/29/2022	Daniel C Javitt	Major Shareholder	Sell	7,840	$101.00	$791,840.00	98,729
6/6/2022	Daniel C Javitt	Major Shareholder	Sell	1,156	$67.00	$77,452.00	127,434
6/3/2022	Daniel C Javitt	Major Shareholder	Sell	2,435	$70.00	$170,450.00	128,590
6/1/2022	Jonathan C Javitt	Insider	Buy	1,000	$5,800.00	$5,800,000.00	1,463
9/15/2021	Robert Besthof	Insider	Sell	400	$1,176.00	$470,400.00
8/23/2021	Alessandra Daigneault	General Counsel	Sell	337	$1,311.00	$441,807.00

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

See why the elites are pouring billions into gold.

SEC Filings (Institutional Ownership Changes) for NRx Pharmaceuticals (NASDAQ:NRXP)

4.27% of NRx Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

NRx Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/14/2024	AdvisorShares Investments LLC	642,632	$0.30M	0.1%	N/A	0.755%
1/25/2024	One Wealth Management Investment & Advisory Services LLC	140,402	$65K	0.0%	N/A	0.165%
11/15/2023	Sabby Management LLC	325,000	$84K	0.1%	-53.6%	0.398%
5/1/2023	Virtu Financial LLC	46,210	$30K	0.0%	N/A	0.065%
2/9/2023	HBK Sorce Advisory LLC	58,460	$65K	0.0%	N/A	0.086%
1/31/2023	AE Wealth Management LLC	29,515	$33K	0.0%	N/A	0.044%
1/27/2023	Exchange Traded Concepts LLC	26,924	$30K	0.0%	+154.0%	0.040%
1/18/2023	Exchange Traded Concepts LLC	26,924	$30K	0.0%	+154.0%	0.040%
11/3/2022	Texas Capital Bank Wealth Management Services Inc.	63,290	$47K	0.0%	N/A	0.094%
5/18/2022	Ursa Fund Management LLC	15,000	$37K	0.0%	N/A	0.023%
4/29/2022	United Asset Strategies Inc.	18,300	$45K	0.0%	N/A	0.027%
2/9/2022	Wolverine Asset Management LLC	37,105	$0.18M	0.0%	-12.8%	0.063%
2/8/2022	Raymond James Financial Services Advisors Inc.	11,567	$55K	0.0%	N/A	0.020%
11/15/2021	Penserra Capital Management LLC	2,956	$27K	0.0%	N/A	0.005%
11/12/2021	Wolverine Asset Management LLC	42,568	$0.39M	0.0%	+118.4%	0.079%
11/5/2021	Advisor Group Holdings Inc.	42,885	$0.40M	0.0%	+1,197.6%	0.080%
11/2/2021	Cambridge Investment Research Advisors Inc.	153,523	$1.42M	0.0%	N/A	0.285%
8/16/2021	Owl Creek Asset Management L.P.	300,000	$3.40M	0.2%	N/A	0.626%
8/16/2021	Ionic Capital Management LLC	35,721	$0.42M	0.0%	N/A	0.075%
8/16/2021	Linden Advisors LP	364,352	$4.23M	0.0%	N/A	0.760%
8/13/2021	Northern Trust Corp	130,633	$1.52M	0.0%	N/A	0.273%
8/13/2021	Yakira Capital Management Inc.	11,923	$0.14M	0.0%	N/A	0.025%
8/13/2021	Geode Capital Management LLC	34,475	$0.40M	0.0%	N/A	0.072%
8/13/2021	Vanguard Group Inc.	637,416	$7.41M	0.0%	N/A	1.330%

Data available starting January 2016

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.

Today's Range

Now: $3.14

$3.01

$3.14

50 Day Range

MA: $33.06

$3.00

$70.06

52 Week Range

Now: $3.14

$2.21

$12.00

Volume

102,030 shs

Average Volume

178,094 shs

Market Capitalization

$31.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Who are the company insiders with the largest holdings of NRx Pharmaceuticals?: NRx Pharmaceuticals' top insider investors include:
Jonathan C Javitt (Director)
Daniel C Javitt (Major Shareholder)
Chaim Hurvitz (Director)
Jonathan C Javitt (Insider)
Aaron Gorovitz (Director)
Stephen H Willard (CEO)
Voorhees Seth Van (CFO)
Patrick John Flynn (Director)
Learn More about top insider investors at NRx Pharmaceuticals.